Your browser is no longer supported. Please, upgrade your browser.
ENTA Enanta Pharmaceuticals, Inc. daily Stock Chart
ENTA [NASD]
Enanta Pharmaceuticals, Inc.
Index- P/E30.00 EPS (ttm)2.22 Insider Own3.30% Shs Outstand19.44M Perf Week3.95%
Market Cap1.29B Forward P/E- EPS next Y-3.12 Insider Trans0.00% Shs Float15.83M Perf Month7.42%
Income46.40M PEG- EPS next Q0.63 Inst Own92.20% Short Float14.42% Perf Quarter-4.69%
Sales205.20M P/S6.31 EPS this Y-39.70% Inst Trans2.06% Short Ratio11.58 Perf Half Y-25.27%
Book/sh23.49 P/B2.84 EPS next Y-197.10% ROA9.90% Target Price93.14 Perf Year-8.47%
Cash/sh17.24 P/C3.86 EPS next 5Y- ROE10.50% 52W Range57.15 - 106.80 Perf YTD-5.96%
Dividend- P/FCF19.62 EPS past 5Y4.30% ROI8.10% 52W High-37.63% Beta0.91
Dividend %- Quick Ratio17.80 Sales past 5Y33.90% Gross Margin- 52W Low16.55% ATR1.78
Employees132 Current Ratio17.80 Sales Q/Q-23.70% Oper. Margin17.90% RSI (14)65.37 Volatility2.04% 3.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.20% Profit Margin22.60% Rel Volume0.82 Prev Close65.66
ShortableYes LT Debt/Eq0.00 EarningsNov 21 AMC Payout0.00% Avg Volume197.07K Price66.61
Recom2.60 SMA205.48% SMA508.22% SMA200-15.22% Volume161,479 Change1.45%
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Oct-23-15Downgrade Barclays Equal Weight → Underweight $45 → $16
Aug-07-15Reiterated Barclays Equal Weight $35 → $45
Apr-06-15Initiated Deutsche Bank Buy $42
Mar-04-15Initiated Barclays Equal Weight $35
Aug-15-14Initiated FBR Capital Outperform $52
Jun-24-14Downgrade Robert W. Baird Outperform → Neutral
Dec-11-19 11:25AM  Is Enanta Pharmaceuticals Inc (ENTA) A Good Stock To Buy? Insider Monkey
Dec-09-19 07:38AM  Should You Worry About Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pay Cheque? Simply Wall St.
Dec-07-19 11:24PM  Edited Transcript of ENTA earnings conference call or presentation 21-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-22-19 08:18AM  The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 05:15PM  Enanta Pharmaceuticals (ENTA) Lags Q4 Earnings and Revenue Estimates Zacks
04:00PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Business Wire
07:22AM  The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon Benzinga
Nov-17-19 08:42AM  The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down Benzinga
Nov-14-19 10:30AM  Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Nov-11-19 10:21AM  Is Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) 14% ROE Worse Than Average? Simply Wall St.
07:30AM  Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019 Business Wire
Nov-05-19 04:00PM  Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Business Wire
Oct-27-19 10:29PM  Enanta Pharmaceuticals Inc (ENTA): Hedge Funds In Wait-and-See Mode Insider Monkey
Oct-21-19 04:00PM  Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference Business Wire
Oct-12-19 10:03AM  Is Enanta Pharmaceuticals's (NASDAQ:ENTA) Share Price Gain Of 145% Well Earned? Simply Wall St.
Oct-03-19 07:30AM  New Data from Enantas Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay Business Wire
Sep-30-19 04:48PM  Six Mass. businesses make Fortunes list of 100 fastest-growing companies American City Business Journals
Sep-26-19 04:16PM  This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years Investor's Business Daily -15.11%
11:40AM  Enanta's Stock Down Despite NASH Drug Meeting Goal in Study Zacks
07:54AM  The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J Benzinga
Sep-25-19 04:28PM  UPDATE 1-Enanta Pharma's NASH drug meets mid-stage study goal Reuters
04:12PM  Enanta Pharma's liver disease drug meets mid-stage study goal Reuters
04:00PM  Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH Business Wire
Sep-12-19 09:48AM  Is Enanta Pharmaceuticals (NASDAQ:ENTA) A Risky Investment? Simply Wall St.
Sep-10-19 07:30AM  New Data from Enantas Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek 2019 Business Wire
Aug-21-19 07:30AM  Enanta Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference Business Wire
Aug-19-19 02:54PM  Edited Transcript of ENTA earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-13-19 01:24PM  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Aug-07-19 12:37PM  Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 05:55PM  Enanta Pharmaceuticals (ENTA) Q3 Earnings Surpass Estimates Zacks
04:00PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Business Wire
Aug-02-19 08:51AM  Enantas HCV Collaboration Partner AbbVie receives Approval by the European Commission for MAVIRET (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve HCV Patients with Compensated Cirrhosis Business Wire
Jul-30-19 10:38AM  Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Jul-15-19 07:30AM  Enanta Pharmaceuticals to Host Conference Call on August 6 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Business Wire
Jul-11-19 09:00AM  Enanta Pharmaceuticals (ENTA) Upgraded to Strong Buy: Here's What You Should Know Zacks
Jul-08-19 07:30AM  Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV) Business Wire
Jun-14-19 02:06PM  Enanta's Respiratory Virus Drug Aces Midstage Study Benzinga -11.85%
11:12AM  How Much Did Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Pocket Last Year? Simply Wall St.
09:51AM  UPDATE 1-Enanta's lung infection therapy succeeds in mid-stage trial Reuters
06:00AM  REFILE-Enanta's lung infection therapy succeeds in mid-stage trial Reuters
06:00AM  Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV) Business Wire
Jun-10-19 04:00PM  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
08:00AM  AbbVie's MAVIRET now listed on the Nova Scotia and Manitoba formularies CNW Group
May-30-19 08:00AM  AbbVie's MAVIRET now listed in New Brunswick CNW Group
May-15-19 08:23PM  Edited Transcript of ENTA earnings conference call or presentation 7-May-19 8:30pm GMT Thomson Reuters StreetEvents
11:11AM  Do Enanta Pharmaceuticals's (NASDAQ:ENTA) Earnings Warrant Your Attention? Simply Wall St.
May-14-19 04:01PM  Enanta Pharmaceuticals to Present at Upcoming Investor Conference Business Wire
May-07-19 09:00PM  Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript Motley Fool
05:25PM  Enanta Pharmaceuticals (ENTA) Beats Q2 Earnings Estimates Zacks
04:16PM  Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019 Business Wire
May-02-19 02:22PM  Heres What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA) Insider Monkey
Apr-30-19 10:32AM  Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-22-19 04:30PM  Enanta Pharmaceuticals to Host Conference Call on May 7th at 4:30 pm ET to Discuss Its Financial Results for Its Fiscal Second Quarter Ended March 31, 2019 Business Wire
Apr-11-19 10:13AM  Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus and Non-Alcoholic Steatohepatitis at The International Liver Congress 2019 Business Wire
09:00AM  AbbVie's MAVIRET now reimbursed in Quebec CNW Group
Apr-05-19 03:32PM  Can You Imagine How Chuffed Enanta Pharmaceuticals's (NASDAQ:ENTA) Shareholders Feel About Its 216% Share Price Gain? Simply Wall St.
Apr-04-19 10:00AM  AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET CNW Group
Apr-01-19 09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
Mar-27-19 05:24AM  Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2019 Business Wire
Mar-18-19 07:30AM  Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies Business Wire
Mar-11-19 07:30AM  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Feb-15-19 07:35AM  Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire +6.34%
Feb-10-19 11:22PM  Edited Transcript of ENTA earnings conference call or presentation 6-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-06-19 08:43PM  Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:10PM  Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates Zacks
04:07PM  Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018 Business Wire
Jan-30-19 10:31AM  Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy? Zacks
Jan-22-19 12:09PM  Do You Like Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) At This P/E Ratio? Simply Wall St.
08:00AM  Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018 Business Wire
Jan-18-19 06:16PM  Edited Transcript of ENTA earnings conference call or presentation 26-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-03-19 08:00AM  Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-20-18 08:00AM  Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-15-18 11:23AM  Here is What Hedge Funds Think About Enanta Pharmaceuticals Inc (ENTA) Insider Monkey
Dec-05-18 10:28AM  Is Enanta Pharmaceuticals Incs (NASDAQ:ENTA) CEO Pay Fair? Simply Wall St.
Nov-29-18 04:48PM  Enanta Pharmaceuticals Inc (ENTA) Files 10-K for the Fiscal Year Ended on September 30, 2018 GuruFocus.com
Nov-26-18 07:34PM  Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:16PM  Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire
Nov-19-18 10:30AM  Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Nov-13-18 11:40AM  Enanta Announces that AbbVies MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis Business Wire
11:30AM  AbbVie's MAVYRET (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis PR Newswire
Nov-07-18 10:10AM  Why the Earnings Surprise Streak Could Continue for Enanta Pharmaceuticals (ENTA) Zacks
Oct-29-18 07:30AM  Enanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Business Wire -5.95%
Oct-26-18 08:15AM  Report: Developing Opportunities within Assured Guaranty, Potbelly, Enanta Pharmaceuticals, Seagate Technology, Ctrip.com International, and CyberArk Software Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-23-18 07:30AM  Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus Business Wire
Oct-11-18 01:31PM  How Good Is Enanta Pharmaceuticals Inc (NASDAQ:ENTA), When It Comes To ROE? Simply Wall St.
Oct-05-18 11:00AM  Liver Cancers Rising - Stocks to Watch ACCESSWIRE
Sep-25-18 08:45AM  Recent Analysis Shows Enanta Pharmaceuticals, Multi-Color, Otter Tail, Franklin Resources, CubeSmart, and EnPro Industries Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Sep-05-18 07:30AM  Enanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium Business Wire
Sep-04-18 12:01AM  Edited Transcript of ENTA earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-27-18 04:01PM  Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire
Aug-13-18 06:00AM  Why Enanta Stock Is Still a Strong Buy With Huge Upside InvestorPlace -7.46%
Aug-07-18 05:35PM  Enanta Pharmaceuticals (ENTA) Q3 Earnings and Revenues Top Estimates Zacks -8.48%
04:32PM  Enanta Pharmaceuticals: Fiscal 3Q Earnings Snapshot Associated Press
04:01PM  Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire
Aug-02-18 10:08AM  Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA) Zacks
Jul-16-18 07:30AM  Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Business Wire
Jun-27-18 10:39AM  Achieve Life Sciences' Shares Rise on Positive Clinical Data Zacks
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gardiner Nathaniel S.Sr. VP & General CounselNov 22Option Exercise31.421,59250,02119,739Nov 25 05:01 PM
Luly Jay R.President and CEOOct 08Option Exercise14.187,05299,997638,246Oct 09 05:17 PM
Gardiner Nathaniel S.Sr. VP & General CounselSep 27Option Exercise30.005,000150,00019,871Sep 30 04:45 PM
Gardiner Nathaniel S.Sr. VP & General CounselJun 26Option Exercise31.423,295103,52914,871Jun 26 06:33 PM
CARTER BRUCE L ADirectorMar 11Option Exercise23.401,54636,1761,546Mar 12 04:51 PM
CARTER BRUCE L ADirectorMar 11Sale99.161,546153,3010Mar 12 04:51 PM
Gardiner Nathaniel S.Sr. VP & General CounselMar 06Option Exercise33.662,51984,80226,497Mar 07 04:20 PM
Golumbeski GeorgeDirectorMar 04Option Exercise36.619,280339,7419,280Mar 06 04:51 PM
Golumbeski GeorgeDirectorMar 04Sale103.659,280961,8970Mar 06 04:51 PM
Or Yat SunSr. VP & CSOMar 01Sale103.5310,0001,035,320300,673Mar 04 06:14 PM
MELLETT PAUL JTreasurer and CFOFeb 13Option Exercise1.516,96010,49997,188Feb 25 04:18 PM
Gardiner Nathaniel S.Sr. VP & General CounselFeb 13Sale95.283,270311,56223,978Feb 13 09:28 PM
CARTER BRUCE L ADirectorFeb 12Option Exercise23.405,000117,0005,000Feb 13 08:50 PM
Golumbeski GeorgeDirectorFeb 12Option Exercise27.8811,228313,01211,228Feb 13 08:57 PM
CARTER BRUCE L ADirectorFeb 12Sale90.005,000450,0000Feb 13 08:50 PM
Golumbeski GeorgeDirectorFeb 12Sale90.0711,2281,011,3010Feb 13 08:57 PM
Or Yat SunSr. VP & CSOFeb 12Sale90.076,297567,173301,916Feb 13 09:11 PM
Or Yat SunSr. VP & CSOFeb 11Option Exercise13.1825,977342,402335,897Feb 13 09:11 PM
CARTER BRUCE L ADirectorFeb 11Option Exercise23.402,73463,9762,734Feb 13 08:50 PM
Golumbeski GeorgeDirectorFeb 11Option Exercise25.582,27258,1182,272Feb 13 08:57 PM
Golumbeski GeorgeDirectorFeb 11Sale90.032,272204,5520Feb 13 08:57 PM
CARTER BRUCE L ADirectorFeb 11Sale90.022,734246,1020Feb 13 08:50 PM
Or Yat SunSr. VP & CSOFeb 11Sale89.3927,6842,474,737308,213Feb 13 09:11 PM
Gardiner Nathaniel S.Sr. VP & General CounselJan 22Option Exercise34.702,00069,40017,827Jan 24 05:21 PM